Callaghan Brian C, Xia Rong, Banerjee Mousumi, de Rekeneire Nathalie, Harris Tamara B, Newman Anne B, Satterfield Suzanne, Schwartz Ann V, Vinik Aaron I, Feldman Eva L, Strotmeyer Elsa S
Department of Neurology, University of Michigan, Ann Arbor, MI
School of Public Health, University of Michigan, Ann Arbor, MI.
Diabetes Care. 2016 May;39(5):801-7. doi: 10.2337/dc16-0081. Epub 2016 Mar 10.
Previous studies demonstrate that the metabolic syndrome is associated with distal symmetric polyneuropathy (DSP). We aimed to determine the magnitude of this effect and the precise components involved.
We determined the symptomatic DSP prevalence in the Health, Aging, and Body Composition (Health ABC) study (prospective cohort study, with subjects aged 70-79 years at baseline), stratified by glycemic status (glucose tolerance test) and the number of additional metabolic syndrome components (updated National Cholesterol Education Program/Adult Treatment Panel III definition). DSP was defined as neuropathic symptoms (questionnaire) plus at least one of three confirmatory tests (heavy monofilament, peroneal conduction velocity, and vibration threshold). Multivariable logistic and linear regression evaluated the association of metabolic syndrome components with DSP in cross-sectional and longitudinal analyses.
Of 2,382 participants with neuropathy measures (mean age 73.5 ± 2.9 years, 38.2% black, 51.7% women), 21.0% had diabetes, 29.9% prediabetes, 52.8% metabolic syndrome, and 11.1% DSP. Stratified by glycemic status, DSP prevalence increased as the number of metabolic syndrome components increased (P = 0.03). Diabetes (cross-sectional model, odds ratio [OR] 1.65 [95% CI 1.18-2.31]) and baseline hemoglobin A1C (longitudinal model, OR 1.42 [95% CI 1.15-1.75]) were the only metabolic syndrome measures significantly associated with DSP. Waist circumference and HDL were significantly associated with multiple secondary neuropathy outcomes.
Independent of glycemic status, symptomatic DSP is more common in those with additional metabolic syndrome components. However, the issue of which metabolic syndrome components drive this association, in addition to hyperglycemia, remains unclear. Larger waist circumference and low HDL may be associated with DSP, but larger studies with more precise metabolic measures are needed.
既往研究表明,代谢综合征与远端对称性多发性神经病(DSP)相关。我们旨在确定这种关联的程度以及涉及的具体成分。
我们在健康、衰老与身体成分研究(Health ABC,前瞻性队列研究,基线时受试者年龄为70 - 79岁)中,根据血糖状态(葡萄糖耐量试验)和其他代谢综合征成分的数量(更新的美国国家胆固醇教育计划/成人治疗小组第三次报告定义)对有症状的DSP患病率进行分层。DSP被定义为神经病变症状(问卷调查)加上三项确认性检查(粗单丝检查、腓总神经传导速度和振动觉阈值)中的至少一项。多变量逻辑回归和线性回归在横断面和纵向分析中评估代谢综合征成分与DSP的关联。
在2382名进行了神经病变测量的参与者中(平均年龄73.5±2.9岁,38.2%为黑人,51.7%为女性),21.0%患有糖尿病,29.9%为糖尿病前期,52.8%患有代谢综合征,11.1%患有DSP。按血糖状态分层,DSP患病率随代谢综合征成分数量的增加而升高(P = 0.03)。糖尿病(横断面模型,比值比[OR]1.65[95%置信区间1.18 - 2.31])和基线糖化血红蛋白A1C(纵向模型,OR 1.42[95%置信区间1.15 - 1.75])是与DSP显著相关的仅有的代谢综合征指标。腰围和高密度脂蛋白与多种继发性神经病变结局显著相关。
独立于血糖状态,有症状的DSP在具有其他代谢综合征成分的人群中更为常见。然而,除高血糖外,哪些代谢综合征成分驱动这种关联的问题仍不清楚。腰围较大和高密度脂蛋白水平较低可能与DSP相关,但需要更大规模且代谢测量更精确的研究。